GILEAD SCIENCES, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
GILEAD SCIENCES, INC. (GILD) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-26.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2019-02-26
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2017-09-30 was 0.00 shares.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2017-06-30 was 0.00 shares.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2017-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2016-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2018 was 0.00 shares.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2017 was 0.00 shares, a 100.00% decline from fiscal 2016.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2016 was 2.00M shares, a 85.71% decline from fiscal 2015.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2015 was 14.00M shares, a 53.33% decline from fiscal 2014.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2018-12-31 | 0.00 shares 10-K · filed 2019-02-26 | |||
| 2017-12-31 | 0.00 shares 10-K · filed 2019-02-26 | |||
| 2017-09-30 | 0.00 shares 10-Q · filed 2017-11-07 | 0.00 shares 10-Q · filed 2017-11-07 | ||
| 2017-06-30 | 0.00 shares 10-Q · filed 2017-08-07 | 0.00 shares 10-Q · filed 2017-08-07 | ||
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | 2.00M shares 10-K · filed 2019-02-26 | |||
| 2016-09-30 | 0.00 shares 10-Q · filed 2017-11-07 | 2.00M shares 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | 0.00 shares 10-Q · filed 2017-08-07 | 3.00M shares 10-Q · filed 2017-08-07 | ||
| 2016-03-31 | 7.00M shares 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | 14.00M shares 10-K · filed 2018-02-27 | |||
| 2015-09-30 | 12.00M shares 10-Q · filed 2016-11-07 | 14.00M shares 10-Q · filed 2016-11-07 | ||
| 2015-06-30 | 14.00M shares 10-Q · filed 2016-08-05 | 15.00M shares 10-Q · filed 2016-08-05 | ||
| 2015-03-31 | 16.00M shares 10-Q · filed 2016-05-06 | |||
| 2014-12-31 | 30.00M shares 10-K · filed 2017-02-27 | |||
| 2014-09-30 | 27.00M shares 10-Q · filed 2015-11-04 | 32.00M shares 10-Q · filed 2015-11-04 | ||
| 2014-06-30 | 31.00M shares 10-Q · filed 2015-08-05 | 35.00M shares 10-Q · filed 2015-08-05 | ||
| 2013-12-31 | 63.00M shares 10-K · filed 2016-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |